Menu

ViaDerma

About ViaDerma

Posts by ViaDerma :

ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More

ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More

LOS ANGELES, July 06, 2023 (Yahoo! Finance) – ViaDerma, Inc. (OTC Pink: VDRM) is very pleased to announce several exciting business updates for current and prospective shareholders, partners, and healthcare providers. 

The company is currently over 30% through the process of our stability testing requirements in order to finalize approvals for distributing lead product Vitastem Ultra throughout multiple countries in the Caribbean and Middle East. Based on the feedback we have received to date, we anticipate that the required testing protocols should be completed by the end of August or in early September of this year. 

Our new hair regrowth product, Nupelo, is in the final stages of receiving FDA-registered product approval. Recently, our team received feedback and a new request by the FDA to submit additional information required for final approvals. The requirements were sent back to the FDA in early June and we are awaiting the confirmation for FDA-registered approval for Nupelo any day now.

In addition, the company is currently finalizing an agreement with a much larger FDA-registered product manufacturing facility that can help scale Vitastem product inventory to over 100,000 units with just 6-8 weeks lead time. This move is imperative to the company’s success in being able to fulfill increased customer demand throughout the US and around the world.

The company has been working very hard to overcome several scalability challenges we had unexpectedly encountered with our previous product manufacturer who proved unable to fulfill the needed product inventory fast enough in order to meet the volume requirements demanded from healthcare providers and medical supply distributors. Since then, management has thoroughly researched, vetted, and sourced a new Tier-1 FDA-registered medical product manufacturer here in the US who will soon take over all of the manufacturing requirements for Vitastem Ultra. This strategic move will drastically help ViaDerma scale the business much more successfully moving forward in order to meet the increased demand by healthcare professionals and health care supply distributors that have been attributed to our ongoing sales & marketing efforts throughout the world. 

Furthermore, over the past several weeks, the company has interviewed several auditors, CPA firms, and attorneys with the expectations of retaining their services very soon in order to complete the two years of audited financial statements required to become fully SEC reporting. Once completed, the company plans to immediately apply for uplisting ViaDerma to the OTCQB.

ViaDerma is deeply committed to expanding the growth of our business to great new heights in 2023 and even more so into 2024 and beyond. Feedback from healthcare providers in the US and abroad has been stellar and the demand for Vitastem as a go-to topical antibiotic for minor to severe wounds and infectious skin diseases continues to increase by the day. 

The company’s management team deeply appreciates the ongoing feedback and patience from shareholders, partners, and healthcare providers. We are extremely grateful and excited about the future of the business over the next year and look forward to sharing several more updates as soon as possible. 

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. 

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:
Investor Relations
Email: [email protected]
Phone: 310-734-6111
Follow ViaDerma on Twitter: https://twitter.com/viaderma 
Follow ViaDerma on Facebook: https://www.facebook.com/ViaDermaLicensing 

ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product

ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product

The Company unveils brand name for its planned minoxidil hair regrowth product

LOS ANGELES, March 16, 2023 (Yahoo! Finance) – ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce that the company has recently submitted their application for their planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and we expect this process to be completed within a few weeks.

The company has chosen Nupelo as the brand name for its new hair regrowth product. Nupelo will incorporate ViaDerma’s proprietary, patent-pending dual carrier transdermal delivery technology and use Minoxidil (topical route) in their new hair regrowth product.

ViaDerma plans to make Nupelo available for purchase via several online platforms including their newly acquired domain, nupelo.com. The product is expected to be ready to go to market and available to purchase online by the end of Q2 2023.

“Everything has really come together very quickly and smoothly. Due to the extreme effectiveness of our proprietary transdermal delivery system, we are able to develop new products like Nupelo in a very short period of time. Many other hair products only work to reduce hair loss, but are ineffective at actually regrowing hair. Nupelo works to solve both,” said ViaDerma’s President & CEO, Dr. Chris Otiko.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: https://viaderma.com

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:
Investor Relations
Email: [email protected]
Phone: 310-734-6111
Follow Nupelo on Twitter: https://twitter.com/TryNupelo
Follow Nupelo on Facebook: https://www.facebook.com/TryNupelo

ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product

ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product

LOS ANGELES, March 08, 2023 (Benzinga) – ViaDerma, Inc. (OTC: VDRM) is pleased to announce their plans to launch a new hair regrowth product using Minoxidil (topical route). The company will incorporate their proprietary, patent-pending dual carrier transdermal delivery technology with Minoxidil to create their new hair regrowth product. 

ViaDerma’s unique transdermal delivery system facilitates the transfer of chemicals through the stratum corneum, the outermost layer of the skin with a diffusion constant that is 10,000x higher than other products on the market. This allows much more of the active ingredient to be absorbed into the skin and work better and faster, often producing significantly better results than traditional topical treatments. Previous testing conducted by ViaDerma has yielded exceptional results at regrowing hair. 

A recently published report showed the global Minoxidil market size was valued at USD 1.038 billion in 2022 and is expected to expand at a CAGR of 5.48% during the forecast period, reaching USD 1.43 billion by 2028. The global hair restoration market as a whole which includes surgical and noninvasive treatments is expected to reach USD 13.6 billion by 2028, according to this research report by Grand View Research. Minoxidil is the active ingredient in several top selling hair regrowth products including Rogaine, Rogaine Extra Strength, and Lipogaine.

ViaDerma’s President & CEO, Dr. Chris Otiko said, “We are very excited to announce these plans for our new product and to enter this rapidly expanding industry. Our objective is to create the best hair regrowth product on the market.”  

FDA registration of the product is expected to be completed within the next 90 days. The company expects to have the new product on the market later this year. 

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: ViaDerma.com

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:
Investor Relations
Email:  ir@viaderma.com
Phone: 310-734-6111
Follow ViaDerma on Twitter: https://twitter.com/viaderma
Follow ViaDerma on Facebook: https://www.facebook.com/ViaDermaLicensing/

ViaDerma Provides an Update on Current & Future Business Activities

ViaDerma Provides an Update on Current & Future Business Activities

The Company has expanded its current wound care licensing agreement to 11 states and expects to be nationwide within the next 12 months

LOS ANGELES, March 02, 2023 (Yahoo! Finance) – ViaDerma, Inc. (OTC Pink: VDRM) is pleased to provide an update on current business activities.

  • ViaDerma has expanded its licensing agreement with a large wound care network. The licensee recently increased the number of states in which they operate to eleven. Per the agreement, ViaDerma receives $5,000 per month for each state in which the licensee is doing business. The addition of the new states increases ViaDerma’s current royalties to $55,000 per month from this agreement. The wound care network has indicated their intent to add new states at a more rapid pace and believes they can be nationwide within the next twelve months.

  • The Company has recently launched a new corporate website which is now ViaDerma.com. Redesigning the website was an important step in the company’s ongoing efforts to develop and grow the brand by increasing name recognition, customer engagement, and new business worldwide.

  • ViaDerma is currently in the process of seeking approval for insurance coverage benefits for Vitastem and Vitastem Ultra. Many insurance companies including Medicare and Medicaid offer over-the-counter benefits (OTC) for non-prescription or OTC products such as the products offered by ViaDerma.

President & CEO, Dr. Chris Otiko said, “We are off to a great start in this new year after enduring some delays because of pandemic related supply chain issues and our strict internal quality control measures. We are happy to be back on track and very excited for what the future holds.”

“Our current marketing efforts are geared towards targeting institutions, hospitals, and doctor’s offices domestically and internationally for product sales, along with licensing the use of Vitastem and Vitastem Ultra. So far, we have received overwhelmingly positive feedback from those who have tested our products and expect this to result in larger volume sales in 2023.”

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: Viaderma.com

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:

Investor Relations

Email:  [email protected]

Phone: 310-734-6111

Follow ViaDerma on Twitter: https://twitter.com/viaderma

Follow ViaDerma on Facebook: https://www.facebook.com/ViaDermaLicensing/

ViaDerma Retains Digital Marketing Leader INTENT SCIENCES to Accelerate Business Growth Online

ViaDerma Retains Digital Marketing Leader INTENT SCIENCES to Accelerate Business Growth Online

ViaDerma, Inc. (OTC Pink: VDRM) is extremely pleased to announce that they have retained the global digital marketing agency leader INTENT SCIENCES to manage and scale their business growth online via branding, SEO, social media, content marketing, and more throughout 2023. 

INTENT SCIENCES is a leading digital marketing agency that specializes in comprehensive go-to-market strategies, SEO (search engine optimization), CRO (conversion rate optimization), social media, press, content marketing, brand development, and more. To date, they have helped dozens of Silicon Valley & international venture-backed startups to Fortune 500 brands generate over $1 billion in revenue online. You can learn more about their comprehensive business experience here.

“We are extremely thrilled to bring on INTENT SCIENCES at this time and to help us move the business forward in this new year. We have seen their results with other companies, and we are convinced their team will greatly help us build the Vitastem brand and drastically increase our revenues for 2023 and beyond.” said ViaDerma President & CEO, Dr. Chris Otiko. 

The INTENT SCIENCES marketing team will be working very closely with ViaDerma’s management to help grow the business with advanced B2B & B2C digital marketing campaigns.

“We’re honored and very excited to be working with ViaDerma to help grow the brand and business online. Vitastem is an incredible first aid & antibiotic ointment that works miracles. The world needs to know about the immense value Vitastem provides and we intend to introduce the brand to millions of people online everywhere.” said Michael Balducci, Founder & CEO at INTENT SCIENCES. 

“There is an incredible amount of search demand for the many ailments Vitastem is a great solution for. According to primary Google data, there are well over 35 million searches on average each month for several issues Vitastem is an immediate remedy for. From common bacterial skin infections like psoriasis, eczema, diabetic ulcers, acne scars, MRSA, and impetigo to post-op surgical wounds, cuts & scrapes, toenail fungus, first to third-degree burns, and pet wounds too. We intend to help connect Vitastem with those searchers via very advanced SEO strategies, amongst other ongoing brand building campaigns.” said Balducci. 

ViaDerma also announced they are continuing to pursue several large purchase orders they are confident could be finalized soon. The company intends to follow up with these endeavors soon. 

About ViaDerma, Inc.

ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. 

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

ViaDerma Successfully Completes Quality Control Testing of its New Vitastem Products

ViaDerma Successfully Completes Quality Control Testing of its New Vitastem Products

LOS ANGELES, Sept. 15, 2022 (GLOBE NEWSWIRE) ViaDerma, Inc., (OTC Pink: VDRM) announces the successful completion of its internal quality control testing for their new Vitastem products. The Company implemented the testing as an additional precautionary safeguard since both products, Vitastem and Vitastem Ultra are using new formulations. The initial shipment of the new products has been received by ViaDerma allowing the Company to resume their online product sales.

The new and improved Vitastem and Vitastem Ultra are FDA-registered drugs and are among the strongest and most effective topical antibiotics available on the market. Vitastem kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing (bacteria that is associated with acne, cuts, scrapes, burns, and secondary infections associated with psoriasis and eczema).

Vitastem Ultra uses bacitracin as the active ingredient and the new formula is clear and colorless compared to the brownish color of the original (which has tetracycline as the active ingredient), so it will not stain the skin, fingernails, toenails, or anywhere else it is applied. Both Vitastem and Vitastem Ultra work similarly and provide the same great results. The new formulation with bacitracin provides an alternative for consumers who are allergic or resistant to one or the other.

President and CEO, Dr. Chris Otiko said, “As expected, the testing was successful which now allows us to confidently move forward with our new products. Having the products back in stock not only puts us in the position to restart our online sales, but also opens the door for us to resume discussions for pending purchase orders we had been working on for some time.

Dr. Otiko also said, “We anticipate filing our second quarter financial report with OTC Markets within the next few days. The delay was due to some missing information which we expect will be resolved very shortly.”

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas.

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products

ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products

LOS ANGELES, June 22, 2022 (GLOBE NEWSWIRE) — ViaDerma, Inc., (“Company”) (OTC Pink: VDRM) announces plans to conduct additional internal quality control testing for their new Vitastem products. Vitastem and Vitastem Ultra are manufactured at a contract facility in the United States and have successfully undergone all standard testing required by regulators. Following extensive consultation with the Company’s manufacturing partners and potential purchasers and distributors of the products, the decision was made to implement further testing as an additional precautionary measure since both products are using new formulations. 

The new and improved Vitastem and Vitastem Ultra are FDA-registered drugs and are among the strongest and most effective topical antibiotics available on the market. Vitastem kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing (bacteria that is associated with acne, cuts, scrapes, burns, and secondary infections associated with psoriasis and eczema). Vitastem Ultra uses bacitracin as the active ingredient and the new formula is clear and colorless compared to the brownish color of the original (which has tetracycline as the active ingredient), so it will not stain the skin, fingernails, toenails, or anywhere else it is applied. Both Vitastem and Vitastem Ultra work similarly and provide the same great results. The new formulation with bacitracin provides an alternative for consumers who are allergic or resistant to one or the other.

President and CEO, Dr. Chris Otiko said, “Since both of these products are a new and improved formulation, we decided now would be the best time to conduct additional testing before we begin large scale distribution.”

Dr. Otiko continued, “The products have tested well so far, and we expect they will continue to do so without issue, but because they are both different formulations than the original, and since we are moving much closer to having to fulfill large purchase orders, we felt we should implement these precautionary measures at this time in an abundance of caution. The last thing we want is to have a problem down the road when a correction would be much harder to address. Taking this step now will minimize the potential for such problems later.”

The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after. 

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. 

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

ViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem Ultra

ViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem Ultra

LOS ANGELES, Oct. 04, 2021 (GLOBE NEWSWIRE) — ViaDerma, Inc., (OTC Pink: VDRM) is pleased to announce they are launching two new and improved formulas for its top selling product, Vitastem and Vitastem Ultra.

The original Vitastem is an FDA-registered drug and one of the world’s strongest topical antibiotics. Its active ingredient is tetracycline. Vitastem kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing (bacteria that is associated with acne, cuts, scrapes, burns, and secondary infections associated with psoriasis and eczema). The new formula is clear and colorless compared to the brownish color of the original, so it will not stain the skin, fingernails, toenails, or anywhere else it is applied.

The Company is also unveiling its new Vitastem Ultra. The active ingredient in Vitastem Ultra is bacitracin. This provides an alternative for people who are allergic to tetracycline, as well as a way to treat tetracycline resistant bacteria. Additionally, Vitastem Ultra will open new doors overseas in many markets that prefer tetracycline alternatives. Like the new and improved Vitastem, Vitastem Ultra is colorless and non-staining. Batches of the new products are currently being produced and are expected to be available to consumers on Amazon, Vitastem.net and other ViaDerma resellers by mid-October. The old version will no longer be sold, and all new and future purchase orders will be filled with the new products.

“I am very excited to get these two new products on the market,” said Dr. Chris Otiko, ViaDerma President and CEO. “Vitastem has always received great reviews, but the one suggestion that came up from time to time was if we can make it non-staining. I am happy to announce we have addressed that issue.”

Dr. Otiko also said, “Our new Ultra product is a great alternative for people who cannot use tetracycline. Ultra will provide the same great results as the original.”

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. 

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

ViaDerma, Inc. Files Amended Financial Statements

ViaDerma, Inc. Files Amended Financial Statements

LOS ANGELES, Aug. 24, 2021 (GLOBE NEWSWIRE) ViaDerma, Inc., (OTC Pink: VDRM) published a Quarterly Report for the three months ended March 31, 2021, on the OTC Markets website reporting Convertible Notes Payable of $281,538.00 and a Convertible Line of Credit of $19,000.00.  Two weeks prior, the Company had issued a press release dated March 16, 2021, stating that it had paid off all of its toxic convertible note liabilities. That press release was not accurate, although it was thought to be at the time.

This month, an internal review by VDRM’s accountant determined that the total outstanding convertible debt as of March 31, 2021, was equal to $300,358.00, and this debt was not paid off or settled as stated in its press release.  Separately, the internal review found that VDRM had an unrecorded and non-disclosed liability of $200,000.  The Company has restated its previous financial statements to reflect this liability. The notes in question were originally issued in 2018.

Additionally, the Company is also announcing that the payment from the recently disclosed transaction in Dubai has been paid and received into an escrow account. Release of the funds to ViaDerma is imminent. ViaDerma intends to allocate part of the proceeds from those funds to engage a qualified auditing firm registered with the Public Company Accounting Oversight Board (PCAOB) to complete an audit of ViaDerma’s financials for the previous two years. Audited financials are required before ViaDerma can make application for listing on the OTCQB and become a fully SEC reporting company.

Dr. Chris Otiko, ViaDerma President and CEO, stated, “This was a very regrettable oversight and error on our part. As soon it was brought to my attention, I took swift action to rectify the matter and disclose it to our shareholders. Our accountant has amended our previous filings that were affected by this error, which was the reason for the delay in filing our 2nd quarter financial statement.”

Dr. Otiko also said, “This mistake on our part, while unfortunate, does not diminish our accomplishments so far. Our main product, Vitastem, consistently delivers excellent results to our consumers and is steadily becoming more widely known. We are very enthusiastic about the future of the Company and what lies ahead.”

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. 

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

ViaDerma, Inc. Provides Updates On Current Business Activities

ViaDerma, Inc. Provides Updates On Current Business Activities

LOS ANGELES, June 24, 2021 (GLOBE NEWSWIRE) — ViaDerma, Inc., (“Company”) (OTCPink:VDRM), is pleased to provide an update on current business activities.

  • The Company has finalized a ten-year $12 million licensing agreement in Dubai. Under the terms of the agreement ViaDerma grants licensing rights to sell ViaDerma based products throughout the Middle East. The first semiannual payment of $600,000 has been initiated and will be available to ViaDerma on or before August 5, 2021.

  • ViaDerma’s licensing agreement with a home health wound care network has now expanded to nine states: CA, NV, AZ, TX, TN, GA, OH, FL, IL. As part of the agreement ViaDerma receives royalties of $5000 per month for each state and are on track to reach their target of 16 states by year end. With the newly added state ViaDerma’s monthly revenue from the agreement has increased to $45,000 per month.

  • The Company expects to hire a qualified auditing firm registered with the Public Company Accounting Oversight Board (PCAOB) within the next 30 to 60 days to complete an audit of ViaDerma’s financials. Audited financials are required before ViaDerma can make application for listing on the OTCQB later this year.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. 

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:
Investor Relations
Email:  [email protected]
Phone: 310-734-6111

Load More

Keep in Touch with ViaDerma Updates

Icon label

© ViaDerma, Inc. All Rights Reserved. Privacy Policy

Back To Top